Innovating Works
IMI2-2015-03-03
IMI2-2015-03-03: Linking Clinical Neuropsychiatry and Quantitative Neurobiology
Scope:Specific Challenge The challenge is to initiate the process to move towards a quantitative biology based framework for neuropsychiatry disorders. This is needed both to reverse the stagnation in treatment development of classical psychiatric disorders, and to address the need to treat neuropsychiatric issues associated with the increasing burden of neurodegenerative disease. Scope The overall scope will be to explore the same set of quantifiable biological parameters across selected symptom constellations common to distinctly classified syndromes by classical taxonomy.
Sólo fondo perdido 0 €
Europeo
Esta convocatoria está cerrada Esta línea ya está cerrada por lo que no puedes aplicar. Cerró el pasado día 24-03-2015.
Se espera una próxima convocatoria para esta ayuda, aún no está clara la fecha exacta de inicio de convocatoria.
Por suerte, hemos conseguido la lista de proyectos financiados!
Presentación: Consorcio Consorcio: Esta ayuda está diseñada para aplicar a ella en formato consorcio.
Número mínimo de participantes.
Esta ayuda financia Proyectos: Objetivo del proyecto:

Scope:Specific Challenge The challenge is to initiate the process to move towards a quantitative biology based framework for neuropsychiatry disorders. This is needed both to reverse the stagnation in treatment development of classical psychiatric disorders, and to address the need to treat neuropsychiatric issues associated with the increasing burden of neurodegenerative disease. Scope The overall scope will be to explore the same set of quantifiable biological parameters across selected symptom constellations common to distinctly classified syndromes by classical taxonomy.

These studies would be driven from clinical quantitative biology back through appropriate translation to the measurement of homologous pre-clinical quantitative biological indices. Expected Impact New classification of the disease for stratification of patients to facilitate more effective treatment and design of clinical trials, including the standardisation of measurement across sites.

Identification of best predictive systems- clinical, non-clinical and pre-clinical – to explore the underlying biological process for identification and development of novel therapies or targets Budg... ver más

Scope:Specific Challenge The challenge is to initiate the process to move towards a quantitative biology based framework for neuropsychiatry disorders. This is needed both to reverse the stagnation in treatment development of classical psychiatric disorders, and to address the need to treat neuropsychiatric issues associated with the increasing burden of neurodegenerative disease. Scope The overall scope will be to explore the same set of quantifiable biological parameters across selected symptom constellations common to distinctly classified syndromes by classical taxonomy.

These studies would be driven from clinical quantitative biology back through appropriate translation to the measurement of homologous pre-clinical quantitative biological indices. Expected Impact New classification of the disease for stratification of patients to facilitate more effective treatment and design of clinical trials, including the standardisation of measurement across sites.

Identification of best predictive systems- clinical, non-clinical and pre-clinical – to explore the underlying biological process for identification and development of novel therapies or targets Budget IMI contribution: EUR 8 080 000

EFPIA contribution: EUR 8 080 000

Total: EUR 16 160 000


ver menos

Temáticas Obligatorias del proyecto: Temática principal: Pharmaceutical chemistry Clinical Trials Regulatory framework for innovation Pharmacoeconomics

Características del consorcio

Ámbito Europeo : La ayuda es de ámbito europeo, puede aplicar a esta linea cualquier empresa que forme parte de la Comunidad Europea.
Tipo y tamaño de organizaciones: El diseño de consorcio necesario para la tramitación de esta ayuda necesita de:

Características del Proyecto

Requisitos de diseño: Duración:
Requisitos técnicos: Scope:Specific Challenge The challenge is to initiate the process to move towards a quantitative biology based framework for neuropsychiatry disorders. This is needed both to reverse the stagnation in treatment development of classical psychiatric disorders, and to address the need to treat neuropsychiatric issues associated with the increasing burden of neurodegenerative disease. Scope The overall scope will be to explore the same set of quantifiable biological parameters across selected symptom constellations common to distinctly classified syndromes by classical taxonomy. Scope:Specific Challenge The challenge is to initiate the process to move towards a quantitative biology based framework for neuropsychiatry disorders. This is needed both to reverse the stagnation in treatment development of classical psychiatric disorders, and to address the need to treat neuropsychiatric issues associated with the increasing burden of neurodegenerative disease. Scope The overall scope will be to explore the same set of quantifiable biological parameters across selected symptom constellations common to distinctly classified syndromes by classical taxonomy.
¿Quieres ejemplos? Puedes consultar aquí los últimos proyectos conocidos financiados por esta línea, sus tecnologías, sus presupuestos y sus compañías.
Capítulos financiables: Los capítulos de gastos financiables para esta línea son:
Personnel costs.
Los costes de personal subvencionables cubren las horas de trabajo efectivo de las personas directamente dedicadas a la ejecución de la acción. Los propietarios de pequeñas y medianas empresas que no perciban salario y otras personas físicas que no perciban salario podrán imputar los costes de personal sobre la base de una escala de costes unitarios
Purchase costs.
Los otros costes directos se dividen en los siguientes apartados: Viajes, amortizaciones, equipamiento y otros bienes y servicios. Se financia la amortización de equipos, permitiendo incluir la amortización de equipos adquiridos antes del proyecto si se registra durante su ejecución. En el apartado de otros bienes y servicios se incluyen los diferentes bienes y servicios comprados por los beneficiarios a proveedores externos para poder llevar a cabo sus tareas
Subcontracting costs.
La subcontratación en ayudas europeas no debe tratarse del core de actividades de I+D del proyecto. El contratista debe ser seleccionado por el beneficiario de acuerdo con el principio de mejor relación calidad-precio bajo las condiciones de transparencia e igualdad (en ningún caso consistirá en solicitar menos de 3 ofertas). En el caso de entidades públicas, para la subcontratación se deberán de seguir las leyes que rijan en el país al que pertenezca el contratante
Madurez tecnológica: La tramitación de esta ayuda requiere de un nivel tecnológico mínimo en el proyecto de TRL 5:. Los elementos básicos de la innovación son integrados de manera que la configuración final es similar a su aplicación final, es decir que está listo para ser usado en la simulación de un entorno real. Se mejoran los modelos tanto técnicos como económicos del diseño inicial, se ha identificado adicionalmente aspectos de seguridad, limitaciones ambiéntales y/o regulatorios entre otros. + info.
TRL esperado:

Características de la financiación

Intensidad de la ayuda: Sólo fondo perdido + info
Fondo perdido:
0% 25% 50% 75% 100%
Please read the IMI2 3rd Call Topics Text for full details of this topic, including the budget breakdown.
Please note that submitting proposals for this call can only be done through the IMI SOFIA software tool.
Please read carefully all provisions below before the preparation of your application.
List of countries and applicable rules for funding:
described in article 10(2) of Regulation N° 1290/2013 of 11 December 2013 laying down the rules for participation and dissemination in Horizon 2020 and in article 1 of the Commission Delegated Regulation (EU) N° 622/2014 of 14 February 2014
 
Eligibility and admissibility conditions:
described in the IMI2 Manual for evaluation, submission and grant award. See also the Commission Delegated Regulation (EU) N° 622/2014 of 14 February 2014
 
Evaluation
Guide to the submission and evaluation process including evaluation criteria and procedure, scoring and threshold:
described in the IMI2 Manual for submission, evaluation and grant award.
See also the proposal templates for your specific action in section 6, below.
 
Proposal page limits and layout:
Please refer to the proposal templates for your specific action, see section 6, below.
 
Indicative timetable for evaluation and grant agreement:
Notification of outcomes of Stage 1 evaluations: Maximum 5 months from deadline for submitting prop...
Please read the IMI2 3rd Call Topics Text for full details of this topic, including the budget breakdown.
Please note that submitting proposals for this call can only be done through the IMI SOFIA software tool.
Please read carefully all provisions below before the preparation of your application.
List of countries and applicable rules for funding:
described in article 10(2) of Regulation N° 1290/2013 of 11 December 2013 laying down the rules for participation and dissemination in Horizon 2020 and in article 1 of the Commission Delegated Regulation (EU) N° 622/2014 of 14 February 2014
 
Eligibility and admissibility conditions:
described in the IMI2 Manual for evaluation, submission and grant award. See also the Commission Delegated Regulation (EU) N° 622/2014 of 14 February 2014
 
Evaluation
Guide to the submission and evaluation process including evaluation criteria and procedure, scoring and threshold:
described in the IMI2 Manual for submission, evaluation and grant award.
See also the proposal templates for your specific action in section 6, below.
 
Proposal page limits and layout:
Please refer to the proposal templates for your specific action, see section 6, below.
 
Indicative timetable for evaluation and grant agreement:
Notification of outcomes of Stage 1 evaluations: Maximum 5 months from deadline for submitting proposals
Notification of outcomes of Stage2 evaluations: Maximum 5 months from deadline for submitting full proposals
Signature of grant agreements: maximum 3 months from the date of informing successful applicants.
 
Provisions, proposal templates and evaluation forms
IMI2 Model Grant Agreement
Summary of the most relevant provisions for participating in IMI2 actions
IMI2 RIA/IA Proposal template
IMI2 RIA/IA Evaluation form
Template for essential clinical trial information
Garantías:
No exige Garantías
No existen condiciones financieras para el beneficiario.

Información adicional de la convocatoria

Efecto incentivador: Esta ayuda tiene efecto incentivador, por lo que el proyecto no puede haberse iniciado antes de la presentación de la solicitud de ayuda. + info.
Respuesta Organismo: Se calcula que aproximadamente, la respuesta del organismo una vez tramitada la ayuda es de:
Meses de respuesta:
Muy Competitiva:
No Competitiva Competitiva Muy Competitiva
No conocemos el presupuesto total de la línea
Minimis: Esta línea de financiación NO considera una “ayuda de minimis”. Puedes consultar la normativa aquí.

Otras ventajas

Sello PYME: Tramitar esta ayuda con éxito permite conseguir el sello de calidad de “sello pyme innovadora”. Que permite ciertas ventajas fiscales.
H2020-JTI-IMI2-2015-03-two-stage Linking Clinical Neuropsychiatry and Quantitative Neurobiology Scope:Specific Challenge The challenge is to initiate the process to move towards a quantitative biology based framework for neuropsychiatry...
Sin info.
IMI2-2015-07-04 DRY AGE-RELATED MACULAR DEGENERATION: DEVELOPMENT OF NOVEL CLINICAL ENDPOINTS FOR CLINICAL TRIALS WITH A REGULATORY AND PATIENT ACCESS INTENTION
en consorcio: Specific Challenge:Age-related macular degeneration (AMD) is a chronic disease and among the leading causes of blindness world-wide. Current...
Cerrada hace 9 años | Próxima convocatoria prevista para el mes de
IMI2-2015-07-01 VALIDATION OF TRANSLATIONAL IMAGING METHODS IN DRUG SAFETY ASSESSMENT (TRISTAN)
en consorcio: Specific Challenge:The development of imaging biomarkers both for the pre-clinic and the clinic has the potential to advance safety evaluati...
Cerrada hace 9 años | Próxima convocatoria prevista para el mes de
IMI2-2015-07-05 A COMPREHENSIVE ‘PAEDIATRIC PRECLINICAL POC PLATFORM’ TO ENABLE CLINICAL MOLECULE DEVELOPMENT FOR CHILDREN WITH CANCER
en consorcio: Specific Challenge:Paediatric cancer: 20% of all paediatric cancer remains incurable Long term side effects associated with treatment Can...
Cerrada hace 9 años | Próxima convocatoria prevista para el mes de
IMI2-2015-07-03 PATHOLOGICAL NEURON-GLIA INTERACTIONS IN NEUROPATHIC PAIN
en consorcio: Specific Challenge:Neuropathic pain (NP) is a widespread disease affecting 6-8% of the population, causing great misery, and incurring huge...
Cerrada hace 9 años | Próxima convocatoria prevista para el mes de
IMI2-2015-07-07 INCREASE ACCESS AND USE OF HIGH QUALITY DATA TO IMPROVE CLINICAL OUTCOMES IN HEART FAILURE (HF), ATRIAL FIBRILLATION (AF), AND ACUTE CORONARY SYNDROME (ACS) PATIENTS
en consorcio: Specific Challenge:By 2020, heart disease and stroke will become the leading causes of death and disability worldwide, with the number of fa...
Cerrada hace 9 años | Próxima convocatoria prevista para el mes de